Insomnia Market Assessment and Industry Expansion Strategies 2023

Posted by vinit sawant on April 28th, 2021

Global Insomnia Market - Overview

Insomnia is a common sleep disorder characterized by difficulties in sleep. Insomnia can exist as it’s alone or conjugated with other psychiatric problems. Insomnia is most common is women and the severity may increase in conditions like pregnancy, postpartum, and menopause. The exact cause of insomnia is still a mystery.

Many research has shown that biological, behavioural and psychological factors are responsible for initiating of insomnia. Different types of treatment are available in the market- Pharmacological and non-pharmacological treatment. According to a study published in 2017, it is found that prevalence of insomnia in China was around 15.0% which is lower than the other countries such as 27.1% in USA, 37.2% in France and Italy, 50.5% in Poland, 17.3% in Singapore, and 15.3% in Japan.

The global insomnia market is growing mainly due to the stressful work conditions. According to a recent study report published by the Market Research Future, The global insomnia market size is booming and expected to gain prominence over the forecast period. Global insomnia market is expected to grow at a CAGR of 4.5% during forecasted period of 2017-2023.

Despite these drivers, stringent reimbursement policies, and presence of fake drugs are expected to decline the market growth.

Global Insomnia Market - Competitive Analysis

Eisai, Co. is an old company which into making medicine for the insomnia. Company is a larger player in the Japanese market. Company has acquired the manufacturing rights to make API and as well the IPR right from Chugai and Roche to treat insomnia. The marketing authorization are transferred as well as the transition of marketing activities for Rohypnol from Chugai to Eisai and are applicable from April 1, 2017.

Eisai, Co. Ltd. (Japan), Pfizer (US), Merck & Co Inc (US), Sanofi (France), Takeda Pharmaceutical Company (Japan),  Meda Consumer Healthcare Inc (US), Pernix Therapeutics (US), Purdue Pharma L.P. (US), Johnson & Johnson (US),  Astellas (UK), Biocodex S A (France), and Vanda Pharmaceuticals Inc. (US) are some of the prominent players at the forefront of competition in the insomnia market and are profiled in MRFR Analysis.